The gefitinib long-term responder (LTR) - a cancer stem-like cell story?: Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)
Background: In selected patients with advanced non-small cell lung cancer (NSCLC) the EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI) gefitinib (IRESSA) shows response rates of ≥70% and a significant prolongation of progression free survival (PFS). However, cogent biomarkers...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2012
|
| In: |
Lung cancer
Year: 2012, Jahrgang: 77, Heft: 1, Pages: 183-191 |
| ISSN: | 1872-8332 |
| DOI: | 10.1016/j.lungcan.2012.03.003 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.lungcan.2012.03.003 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0169500212001146 
|
| Verfasserangaben: | Sandra Gottschling, Esther Herpel, Wilfried E. E. Eberhardt, David F. Heigener, Jürgen R. Fischer, Claus-Henning Köhne, Cornelius Kortsik, Thomas Kuhnt, Thomas Muley, Michael Meister, Helge G. Bischoff, Peter Klein, Ines Moldenhauer, Philipp A. Schnabel, Michael Thomas, Roland Penzel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1572070404 | ||
| 003 | DE-627 | ||
| 005 | 20220814114650.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180417s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2012.03.003 |2 doi | |
| 035 | |a (DE-627)1572070404 | ||
| 035 | |a (DE-576)502070404 | ||
| 035 | |a (DE-599)BSZ502070404 | ||
| 035 | |a (OCoLC)1341007168 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gottschling, Sandra |d 1974- |e VerfasserIn |0 (DE-588)122893476 |0 (DE-627)706081889 |0 (DE-576)293466890 |4 aut | |
| 245 | 1 | 4 | |a The gefitinib long-term responder (LTR) - a cancer stem-like cell story? |b Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP) |c Sandra Gottschling, Esther Herpel, Wilfried E. E. Eberhardt, David F. Heigener, Jürgen R. Fischer, Claus-Henning Köhne, Cornelius Kortsik, Thomas Kuhnt, Thomas Muley, Michael Meister, Helge G. Bischoff, Peter Klein, Ines Moldenhauer, Philipp A. Schnabel, Michael Thomas, Roland Penzel |
| 264 | 1 | |c July 2012 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.04.2018 | ||
| 520 | |a Background: In selected patients with advanced non-small cell lung cancer (NSCLC) the EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI) gefitinib (IRESSA) shows response rates of ≥70% and a significant prolongation of progression free survival (PFS). However, cogent biomarkers predicting long-term response to EGFR-TKIs are yet lacking. Cancer stem-like cells (CSC) are thought to play a pivotal role in tumor regeneration and appear to be influenced by the EGFR-pathway. This makes them a promising candidate for predicting long-term response to EGFR-TKIs. Materials and methods: We analyzed pre-therapeutic tissue specimens of a rare and specific subset of previously treated German patients with advanced NSCLC who experienced ≥3 year response to gefitinib within the International IRESSA EAP. 11/20 identified long-term responders (LTRs) had appropriate tissue specimens available. Those were analyzed for EGFR and k-ras (Kirsten rat sarcoma) mutations, EGFR and c-met (met proto-oncogene) amplifications and protein expression of EGFR, E-cadherin/vimentin and the CSC antigens CD133 and BCRP1 (breast cancer resistance protein 1). The results were compared to primary resistant patients (RPs) and intermediate responders (IRs) showing a median response of 8.6 months. Results: Each group consisted of 6 women and 5 men, with 1 squamous cell carcinoma (SCC) and 10 adenocarcinoma (AC). Along the LTRs, all but the SCC had EGFR mutations, whereas the RPs had no EGFR, but k-ras mutations in 5/11 cases. 8/11 IRs had EGFR and 3/11 k-ras mutations, of which 2 occurred concomitantly. One patient of each group had an EGFR and/or c-met amplification. EGFR and E-cadherin/vimentin expression was not different between the groups, whereas CD133 was expressed only in 4/10 LTRs and BCRP1 predominantly in responders. The LTRs showed a substantially longer mean PFS to previous therapies, a substantially lower number of metastatic sites and almost exclusively pulmonary or pleural metastasis. Conclusion: LTRs display established properties of EGFR-TKI responders. Antigens characterizing CSC might identify a fraction of LTRs and matter of interest for further evaluation. | ||
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Cancer stem-like cell | |
| 650 | 4 | |a Long-term response | |
| 650 | 4 | |a Non-small cell lung cancer | |
| 650 | 4 | |a tyrosine kinase inhibitor | |
| 700 | 1 | |a Herpel, Esther |d 1973- |e VerfasserIn |0 (DE-588)12965227X |0 (DE-627)476593662 |0 (DE-576)297767984 |4 aut | |
| 700 | 1 | |a Eberhardt, Wilfried E. E. |e VerfasserIn |0 (DE-588)1058450573 |0 (DE-627)796897654 |0 (DE-576)414636554 |4 aut | |
| 700 | 1 | |a Köhne, Claus-Henning |d 1959- |e VerfasserIn |0 (DE-588)122238206 |0 (DE-627)705825167 |0 (DE-576)293167060 |4 aut | |
| 700 | 1 | |a Kuhnt, Thomas |d 1967- |e VerfasserIn |0 (DE-588)120178990 |0 (DE-627)08050311X |0 (DE-576)292081456 |4 aut | |
| 700 | 1 | |a Muley, Thomas |e VerfasserIn |0 (DE-588)1056885432 |0 (DE-627)794179169 |0 (DE-576)16759284X |4 aut | |
| 700 | 1 | |a Meister, Michael |e VerfasserIn |0 (DE-588)1078792046 |0 (DE-627)839461402 |0 (DE-576)451890108 |4 aut | |
| 700 | 1 | |a Bischoff, Helge |d 1958- |e VerfasserIn |0 (DE-588)111184576 |0 (DE-627)389658286 |0 (DE-576)167287249 |4 aut | |
| 700 | 1 | |a Schnabel, Philipp Albert |d 1953-2021 |e VerfasserIn |0 (DE-588)102254960X |0 (DE-627)717000087 |0 (DE-576)16982750X |4 aut | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 700 | 1 | |a Penzel, Roland |e VerfasserIn |0 (DE-588)102044021X |0 (DE-627)691221316 |0 (DE-576)360421083 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer |d Amsterdam [u.a.] : Elsevier, 1985 |g 77(2012), 1, Seite 183-191 |h Online-Ressource |w (DE-627)320649733 |w (DE-600)2025812-4 |w (DE-576)264627539 |x 1872-8332 |7 nnas |a The gefitinib long-term responder (LTR) - a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP) |
| 773 | 1 | 8 | |g volume:77 |g year:2012 |g number:1 |g pages:183-191 |g extent:9 |a The gefitinib long-term responder (LTR) - a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP) |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lungcan.2012.03.003 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0169500212001146 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180417 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 102044021X |a Penzel, Roland |m 102044021X:Penzel, Roland |d 910000 |d 912000 |e 910000PP102044021X |e 912000PP102044021X |k 0/910000/ |k 1/910000/912000/ |p 16 |y j | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 15 | ||
| 998 | |g 102254960X |a Schnabel, Philipp Albert |m 102254960X:Schnabel, Philipp Albert |d 910000 |d 912000 |e 910000PS102254960X |e 912000PS102254960X |k 0/910000/ |k 1/910000/912000/ |p 14 | ||
| 998 | |g 111184576 |a Bischoff, Helge |m 111184576:Bischoff, Helge |d 910000 |d 950000 |d 950900 |e 910000PB111184576 |e 950000PB111184576 |e 950900PB111184576 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 11 | ||
| 998 | |g 1078792046 |a Meister, Michael |m 1078792046:Meister, Michael |d 910000 |d 950000 |d 950900 |e 910000PM1078792046 |e 950000PM1078792046 |e 950900PM1078792046 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 10 | ||
| 998 | |g 1056885432 |a Muley, Thomas |m 1056885432:Muley, Thomas |d 910000 |d 950000 |d 950900 |e 910000PM1056885432 |e 950000PM1056885432 |e 950900PM1056885432 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 9 | ||
| 998 | |g 12965227X |a Herpel, Esther |m 12965227X:Herpel, Esther |d 910000 |d 912000 |e 910000PH12965227X |e 912000PH12965227X |k 0/910000/ |k 1/910000/912000/ |p 2 | ||
| 998 | |g 122893476 |a Gottschling, Sandra |m 122893476:Gottschling, Sandra |d 910000 |d 950000 |d 950900 |e 910000PG122893476 |e 950000PG122893476 |e 950900PG122893476 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 1 |x j | ||
| 999 | |a KXP-PPN1572070404 |e 3006222083 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 17.04.2018"],"language":["eng"],"relHost":[{"title":[{"title_sort":"Lung cancer","title":"Lung cancer","subtitle":"journal of the International Association for the Study of Lung Cancer"}],"disp":"The gefitinib long-term responder (LTR) - a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)Lung cancer","id":{"eki":["320649733"],"issn":["1872-8332"],"zdb":["2025812-4"]},"part":{"extent":"9","volume":"77","issue":"1","pages":"183-191","year":"2012","text":"77(2012), 1, Seite 183-191"},"origin":[{"publisherPlace":"Amsterdam [u.a.]","dateIssuedKey":"1985","publisher":"Elsevier","dateIssuedDisp":"1985-"}],"pubHistory":["1.1985 -"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 20.02.20"],"recId":"320649733","physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"9 S."}],"recId":"1572070404","type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Sandra Gottschling, Esther Herpel, Wilfried E. E. Eberhardt, David F. Heigener, Jürgen R. Fischer, Claus-Henning Köhne, Cornelius Kortsik, Thomas Kuhnt, Thomas Muley, Michael Meister, Helge G. Bischoff, Peter Klein, Ines Moldenhauer, Philipp A. Schnabel, Michael Thomas, Roland Penzel"]},"title":[{"title":"The gefitinib long-term responder (LTR) - a cancer stem-like cell story?","title_sort":"gefitinib long-term responder (LTR) - a cancer stem-like cell story?","subtitle":"Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)"}],"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"July 2012"}],"id":{"eki":["1572070404"],"doi":["10.1016/j.lungcan.2012.03.003"]},"person":[{"given":"Sandra","family":"Gottschling","display":"Gottschling, Sandra","role":"aut"},{"given":"Esther","role":"aut","display":"Herpel, Esther","family":"Herpel"},{"family":"Eberhardt","display":"Eberhardt, Wilfried E. E.","role":"aut","given":"Wilfried E. E."},{"given":"Claus-Henning","display":"Köhne, Claus-Henning","role":"aut","family":"Köhne"},{"given":"Thomas","role":"aut","display":"Kuhnt, Thomas","family":"Kuhnt"},{"given":"Thomas","family":"Muley","display":"Muley, Thomas","role":"aut"},{"display":"Meister, Michael","role":"aut","family":"Meister","given":"Michael"},{"role":"aut","display":"Bischoff, Helge","family":"Bischoff","given":"Helge"},{"family":"Schnabel","display":"Schnabel, Philipp Albert","role":"aut","given":"Philipp Albert"},{"role":"aut","display":"Thomas, Michael","family":"Thomas","given":"Michael"},{"given":"Roland","family":"Penzel","role":"aut","display":"Penzel, Roland"}]} | ||
| SRT | |a GOTTSCHLINGEFITINIBL2012 | ||